Hims & Hers Health Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Hims & Hers Health, Inc. - HIMS

NEW ORLEANS, Oct. 29, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 2, 2026 to file lead plaintiff applications in a securities class action lawsuit against Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS), if they purchased or otherwise acquired the Company's securities between August 4, 2025 and July 29, 2026, inclusive (the “Class Period”).  This action is pending in the United States District Court for the Northern District of California.

GlobeNewsWire • an hour ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hims & Hers Health, Inc. of Class Action Lawsuit and Upcoming Deadlines - HIMS

NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

PRNewsWire • 10 hours ago

HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with SBS Law

LOS ANGELES, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Hims & Hers Health, Inc. (“Hims & Hers” or “the Company”) (NYSE: HIMS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

GlobeNewsWire • 10 hours ago

HIMS November 2, 2026 Lead Plaintiff Deadline - Robbins LLP Reminds Investors About the Opportunity to Lead the Class Action Lawsuit

The complaint alleges that Hims & Hers Health shared private customer information with advertising platforms and engaged in deceptive billing practices.

GlobeNewsWire • 8 hours ago

Hims & Hers Health (HIMS) Alert: Securities Class Action Pending, Investors with Losses Encouraged to Contact Hagens Berman Before November 2, 2026 Lead Plaintiff Deadline

SAN FRANCISCO, Oct. 29, 2026 /PRNewswire/ -- Hims & Hers Health, Inc. (NYSE: HIMS) and certain company executives now face a securities class action lawsuit stemming from the FTC's sweeping federal complaint against the company in which the Commission accuses Hims of serious business misconduct. Hagens Berman, which is actively investigating the alleged claims, encourages HIMS investors who suffered substantial losses to submit your losses now.

PRNewsWire • 11 hours ago

Hims & Hers Health, Inc. (HIMS) Gains As Market Dips: What You Should Know

In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $29.69, marking a +1.24% move from the previous day.

Zacks Investment Research • an hour ago

Teladoc Soars 26% as Revenue and Profit Beat Estimates; Hims & Hers Health and American Well Tick Up

Shrinking revenue hasn't kept Teladoc Health (NYSE:TDOC) from beating estimates on both sales and earnings. Early signs that its BetterHelp mental health business can shift toward insurance-covered care are giving investors a reason to bid the stock up significantly.

24/7 Wall Street • 7 hours ago

Hims Stock Surges After RFK Jr. Eases Access To Unapproved Peptides

Hims stock popped Wednesday after RFK Jr. circumvented the FDA, giving a green light to some unapproved peptides.

Investors Business Daily • Oct 28, 2026

HIMS 5-DAY DEADLINE ALERT: Hims & Hers Health Investors with Significant Losses Encouraged to Contact Hagens Berman Before Nov. 2, 2026 Deadline in Securities Class Action

SAN FRANCISCO, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Hims & Hers Health, Inc. (NYSE: HIMS) and certain company executives now face a securities class action lawsuit stemming from the FTC's sweeping federal complaint against the company in which the Commission accuses Hims of serious business misconduct. Hagens Berman, which is actively investigating the alleged claims, encourages HIMS investors who suffered substantial losses to submit your losses now.

GlobeNewsWire • Oct 28, 2026

HIMS IMPORTANT DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - HIMS

NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hims & Hers Health, Inc. (NYSE: HIMS) between August 4, 2025 and July 29, 2026, both dates inclusive (the “Class Period”), of the important November 2, 2026 lead plaintiff deadline.

GlobeNewsWire • Oct 28, 2026